Development of an SI-traceable magnetic solid-phase extraction coupled with isotope dilution LC-MS/MS method for accurate quantification of alpha-fetoprotein in human serum
Haofeng Sun , Jianyi Liu , Qi Zhang , Lei Yang , Dan Song , Min Zhou , Dewei Song
{"title":"Development of an SI-traceable magnetic solid-phase extraction coupled with isotope dilution LC-MS/MS method for accurate quantification of alpha-fetoprotein in human serum","authors":"Haofeng Sun , Jianyi Liu , Qi Zhang , Lei Yang , Dan Song , Min Zhou , Dewei Song","doi":"10.1016/j.talanta.2025.128606","DOIUrl":null,"url":null,"abstract":"<div><div>Alpha-fetoprotein (AFP) is a critical biomarker widely used for the screening and diagnosis of hepatocellular carcinoma and germ cell tumors. Although immunoassays are commonly employed for AFP detection, significant discrepancies in measurement results across different laboratories persist due to poor harmonization among methods. To improve the accuracy and harmonization of AFP quantification, this study developed a novel magnetic solid-phase extraction coupled with isotope dilution liquid chromatography-tandem mass spectrometry (MSPE-ID-LC-MS/MS) method for the precise measurement of AFP in serum. The method utilizes high-affinity AFP antibodies cocktails conjugated with magnetic nanoparticles to enhance the recovery of low-abundance AFP, combined with optimized elution conditions to ensure analytical reliability. The protocol involves one-step denaturation and alkylation, followed by tryptic digestion. This enables accurate quantification with SI-traceability using three signature peptides. Method validation demonstrated that intra- and inter-day precisions were <10 %, recovery rates of 99.8–101.4 %, and the limit of quantification (LOQ) of 1.5 ng/mL. This work establishes a metrologically robust reference procedure for AFP measurement and paves the way for standardization of clinical protein assays.</div></div>","PeriodicalId":435,"journal":{"name":"Talanta","volume":"297 ","pages":"Article 128606"},"PeriodicalIF":5.6000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Talanta","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039914025010963","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Alpha-fetoprotein (AFP) is a critical biomarker widely used for the screening and diagnosis of hepatocellular carcinoma and germ cell tumors. Although immunoassays are commonly employed for AFP detection, significant discrepancies in measurement results across different laboratories persist due to poor harmonization among methods. To improve the accuracy and harmonization of AFP quantification, this study developed a novel magnetic solid-phase extraction coupled with isotope dilution liquid chromatography-tandem mass spectrometry (MSPE-ID-LC-MS/MS) method for the precise measurement of AFP in serum. The method utilizes high-affinity AFP antibodies cocktails conjugated with magnetic nanoparticles to enhance the recovery of low-abundance AFP, combined with optimized elution conditions to ensure analytical reliability. The protocol involves one-step denaturation and alkylation, followed by tryptic digestion. This enables accurate quantification with SI-traceability using three signature peptides. Method validation demonstrated that intra- and inter-day precisions were <10 %, recovery rates of 99.8–101.4 %, and the limit of quantification (LOQ) of 1.5 ng/mL. This work establishes a metrologically robust reference procedure for AFP measurement and paves the way for standardization of clinical protein assays.
期刊介绍:
Talanta provides a forum for the publication of original research papers, short communications, and critical reviews in all branches of pure and applied analytical chemistry. Papers are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, substantial improvement or advantage over existing technology or methods, and demonstrated analytical applicability. Original research papers on fundamental studies, and on novel sensor and instrumentation developments, are encouraged. Novel or improved applications in areas such as clinical and biological chemistry, environmental analysis, geochemistry, materials science and engineering, and analytical platforms for omics development are welcome.
Analytical performance of methods should be determined, including interference and matrix effects, and methods should be validated by comparison with a standard method, or analysis of a certified reference material. Simple spiking recoveries may not be sufficient. The developed method should especially comprise information on selectivity, sensitivity, detection limits, accuracy, and reliability. However, applying official validation or robustness studies to a routine method or technique does not necessarily constitute novelty. Proper statistical treatment of the data should be provided. Relevant literature should be cited, including related publications by the authors, and authors should discuss how their proposed methodology compares with previously reported methods.